Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares were repurchased at prices ranging between HK$18.19 and HK$18.68, implying a volume-weighted average cost of HK$18.65 per share.

The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.03378%, from 154.23 million to 154.18 million shares. Concurrently, treasury shares increased from 95,200 to 147,300, while total issued shares remained unchanged at 154.33 million. All 52,100 repurchased shares have been retained as treasury stock; none have been cancelled.

Since securing its repurchase mandate on 26 May 2026—authorising purchases of up to 15.43 million shares—Bao Pharma has acquired 147,300 shares, representing 0.10% of the company’s issued share base at the mandate date. A 30-day moratorium on new share issues or treasury share sales is in effect until 5 August 2026, in line with Hong Kong listing rules.

Management affirmed that the buybacks comply with the Hong Kong Stock Exchange’s Main Board Listing Rules and all applicable legal and regulatory requirements.